tiprankstipranks
Shanghai Pharmaceuticals Holding Co Class H (HK:2607)
:2607
Hong Kong Market

Shanghai Pharmaceuticals Holding Co (2607) Income Statement

Compare
4 Followers

Shanghai Pharmaceuticals Holding Co Income Statement

Last quarter (Q3 2024), Shanghai Pharmaceuticals Holding Co's total revenue was ¥70.22B, an increase of 8.16% from the same quarter last year. In Q3, Shanghai Pharmaceuticals Holding Co's net income was ¥1.11B. See Shanghai Pharmaceuticals Holding Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
¥ 260.30B¥ 231.98B¥ 215.82B¥ 191.91B¥ 186.57B
Gross Profit
¥ 30.93B¥ 30.49B¥ 28.54B¥ 27.44B¥ 26.81B
Operating Expenses
¥ 23.26B¥ 21.71B¥ 20.62B¥ 19.30B¥ 18.88B
Depreciation and Amortization
¥ 2.19B¥ 2.22B¥ 2.14B¥ 2.14B¥ 1.88B
EBITDA
¥ 10.90B¥ 12.44B¥ 10.55B¥ 10.44B¥ 9.35B
Operating Income
¥ 7.67B¥ 9.01B¥ 8.21B¥ 7.18B¥ 8.93B
Other Income/Expenses
¥ -612.94M¥ -206.30M¥ -61.67M¥ -8.91M¥ -2.67B
Pretax Income
¥ 7.05B¥ 8.81B¥ 8.14B¥ 7.18B¥ 6.26B
Net Income
¥ 3.77B¥ 5.62B¥ 5.09B¥ 4.50B¥ 4.08B
Per Share Metrics
¥ ―¥ ―¥ ―¥ ―¥ ―
Basic EPS
¥ 1.02¥ 1.61¥ 1.79¥ 1.58¥ 1.44
Diluted EPS
¥ 1.02¥ 1.61¥ 1.79¥ 1.58¥ 1.44
Weighted Average Shares Outstanding
3.70B 3.48B 2.84B 2.84B 2.83B
Weighted Average Shares Outstanding (Diluted)
3.70B 3.49B 2.85B 2.85B 2.83B
Currency in CNY

Shanghai Pharmaceuticals Holding Co Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis